Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Massive hemoptysis in a post-operative patient with recurrent lung cancer successfully treated by the combination therapy of Endobronchial Watanabe Spigot and bronchial artery embolization.
Taoka M, Makimoto G, Umakoshi N, Ninomiya K, Higo H, Kato Y, Fujii M, Kubo T, Ichihara E, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Taoka M, et al. Among authors: maeda y. Respir Med Case Rep. 2022 May 23;38:101669. doi: 10.1016/j.rmcr.2022.101669. eCollection 2022. Respir Med Case Rep. 2022. PMID: 35646587 Free PMC article.
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K, Kiura K. Tamura T, et al. Among authors: maeda y. Biochem Biophys Res Commun. 2018 Jan 1;495(1):360-367. doi: 10.1016/j.bbrc.2017.10.175. Epub 2017 Oct 31. Biochem Biophys Res Commun. 2018. PMID: 29101033
Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
Makimoto G, Ichihara E, Hotta K, Ninomiya K, Oze I, Minami D, Ninomiya T, Kubo T, Ohashi K, Tabata M, Maeda Y, Kiura K. Makimoto G, et al. Among authors: maeda y. Acta Med Okayama. 2018 Jun;72(3):319-323. doi: 10.18926/AMO/56080. Acta Med Okayama. 2018. PMID: 29926012 Free article. Clinical Trial.
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K. Kato Y, et al. Among authors: maeda y. Cancer Sci. 2018 Oct;109(10):3149-3158. doi: 10.1111/cas.13752. Epub 2018 Sep 11. Cancer Sci. 2018. PMID: 30053332 Free PMC article.
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K. Oda N, et al. Among authors: maeda y. Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1. Cancer Chemother Pharmacol. 2018. PMID: 30276451 Clinical Trial.
4,732 results